Skip to Content

QNASL Approval History

  • FDA approved: Yes (First approved March 23rd, 2012)
  • Brand name: QNASL
  • Generic name: beclomethasone dipropionate
  • Dosage form: Nasal Aerosol
  • Company: Teva Pharmaceutical Industries Ltd.
  • Treatment for: Allergic Rhinitis

QNASL (beclomethasone dipropionate) is an intranasal corticosteroid non-aqueous "dry" spray formulation for the treatment of seasonal allergic rhinitis (SAR) and perennial allergic rhinitis (PAR).

Development History and FDA Approval Process for QNASL

Dec 19, 2014Approval Teva Announces FDA Approval of QNASL for Children with Seasonal and Perennial Allergic Rhinitis
Mar 26, 2012Approval Teva Announces FDA Approval of QNASL (beclomethasone dipropionate), a New Nonaqueous Nasal Aerosol, for the Treatment of Allergic Rhinitis
Aug  8, 2011Teva Receives FDA Acceptance of Its New Drug Application for BDP Nasal HFA for the Treatment of Allergic Rhinitis

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.